Compare ERO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | EYPT |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2005 |
| Metric | ERO | EYPT |
|---|---|---|
| Price | $25.31 | $16.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $25.00 | ★ $29.60 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 696.31 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $588,229,000.00 | $42,339,000.00 |
| Revenue This Year | $68.14 | N/A |
| Revenue Next Year | $46.45 | N/A |
| P/E Ratio | $18.98 | ★ N/A |
| Revenue Growth | ★ 26.74 | N/A |
| 52 Week Low | $9.30 | $3.91 |
| 52 Week High | $26.77 | $19.11 |
| Indicator | ERO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 60.28 |
| Support Level | $23.60 | $15.97 |
| Resistance Level | $25.93 | $19.11 |
| Average True Range (ATR) | 1.14 | 0.96 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 72.48 | 46.36 |
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.